142 related articles for article (PubMed ID: 11113943)
1. Comparison of competing risks failure time methods and time-independent methods for assessing strain variations in vaccine protection.
Gilbert PB
Stat Med; 2000 Nov; 19(22):3065-86. PubMed ID: 11113943
[TBL] [Abstract][Full Text] [Related]
2. Interpretability and robustness of sieve analysis models for assessing HIV strain variations in vaccine efficacy.
Gilbert PB
Stat Med; 2001 Jan; 20(2):263-79. PubMed ID: 11169601
[TBL] [Abstract][Full Text] [Related]
3. Sieve analysis: methods for assessing from vaccine trial data how vaccine efficacy varies with genotypic and phenotypic pathogen variation.
Gilbert P; Self S; Rao M; Naficy A; Clemens J
J Clin Epidemiol; 2001 Jan; 54(1):68-85. PubMed ID: 11165470
[TBL] [Abstract][Full Text] [Related]
4. The design and analysis of cholera vaccine trials: recent lessons from Bangladesh.
Clemens J; Sack D; Rao M; Chakraborty J; Kay B; Ahmed F; Khan MR; van Loon FP; Svennerholm AM; Holmgren J
Int J Epidemiol; 1993 Aug; 22(4):724-30. PubMed ID: 8225749
[TBL] [Abstract][Full Text] [Related]
5. Estimation of vaccine efficacy in the presence of waning: application to cholera vaccines.
Durham LK; Longini IM; Halloran ME; Clemens JD; Nizam A; Rao M
Am J Epidemiol; 1998 May; 147(10):948-59. PubMed ID: 9596473
[TBL] [Abstract][Full Text] [Related]
6. Testing and estimation of time-varying cause-specific hazard ratios with covariate adjustment.
Sun Y; Hyun S; Gilbert P
Biometrics; 2008 Dec; 64(4):1070-9. PubMed ID: 18355384
[TBL] [Abstract][Full Text] [Related]
7. The 2-sample problem for failure rates depending on a continuous mark: an application to vaccine efficacy.
Gilbert PB; McKeague IW; Sun Y
Biostatistics; 2008 Apr; 9(2):263-76. PubMed ID: 17704528
[TBL] [Abstract][Full Text] [Related]
8. The potential impact of a moderately effective HIV vaccine with rapidly waning protection in South Africa and Thailand.
Andersson KM; Stover J
Vaccine; 2011 Aug; 29(36):6092-9. PubMed ID: 21703322
[TBL] [Abstract][Full Text] [Related]
9. Mark-specific proportional hazards model with multivariate continuous marks and its application to HIV vaccine efficacy trials.
Sun Y; Li M; Gilbert PB
Biostatistics; 2013 Jan; 14(1):60-74. PubMed ID: 22764174
[TBL] [Abstract][Full Text] [Related]
10. Peru-15 (Choleragarde(®)), a live attenuated oral cholera vaccine, is safe and immunogenic in human immunodeficiency virus (HIV)-seropositive adults in Thailand.
Ratanasuwan W; Kim YH; Sah BK; Suwanagool S; Kim DR; Anekthananon A; Lopez AL; Techasathit W; Grahek SL; Clemens JD; Wierzba TF
Vaccine; 2015 Sep; 33(38):4820-6. PubMed ID: 26241948
[TBL] [Abstract][Full Text] [Related]
11. Mark-specific hazard ratio model with multivariate continuous marks: an application to vaccine efficacy.
Juraska M; Gilbert PB
Biometrics; 2013 Jun; 69(2):328-37. PubMed ID: 23421613
[TBL] [Abstract][Full Text] [Related]
12. A review of the current status of enteric vaccines.
Levine MM; Noriega F
P N G Med J; 1995 Dec; 38(4):325-31. PubMed ID: 9522876
[TBL] [Abstract][Full Text] [Related]
13. Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysis.
Ali M; Emch M; von Seidlein L; Yunus M; Sack DA; Rao M; Holmgren J; Clemens JD
Lancet; 2005 Jul 2-8; 366(9479):44-9. PubMed ID: 15993232
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of a single-dose regimen of inactivated whole-cell oral cholera vaccine: results from 2 years of follow-up of a randomised trial.
Qadri F; Ali M; Lynch J; Chowdhury F; Khan AI; Wierzba TF; Excler JL; Saha A; Islam MT; Begum YA; Bhuiyan TR; Khanam F; Chowdhury MI; Khan IA; Kabir A; Riaz BK; Akter A; Khan A; Asaduzzaman M; Kim DR; Siddik AU; Saha NC; Cravioto A; Singh AP; Clemens JD
Lancet Infect Dis; 2018 Jun; 18(6):666-674. PubMed ID: 29550406
[TBL] [Abstract][Full Text] [Related]
15. Field trials of monovalent Ogawa and Inaba cholera vaccines in rural Bangladesh--three years of observation.
Mosley WH; Aziz KM; Rahman AS; Chowdhury AK; Ahmed A
Bull World Health Organ; 1973; 49(4):381-7. PubMed ID: 4604478
[TBL] [Abstract][Full Text] [Related]
16. Statistical methods for assessing differential vaccine protection against human immunodeficiency virus types.
Gilbert PB; Self SG; Ashby MA
Biometrics; 1998 Sep; 54(3):799-814. PubMed ID: 9750238
[TBL] [Abstract][Full Text] [Related]
17. Field trial of oral cholera vaccines in Bangladesh.
Clemens JD; Sack DA; Harris JR; Chakraborty J; Khan MR; Stanton BF; Kay BA; Khan MU; Yunus M; Atkinson W
Lancet; 1986 Jul; 2(8499):124-7. PubMed ID: 2873397
[TBL] [Abstract][Full Text] [Related]
18. Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up.
Clemens JD; Sack DA; Harris JR; Van Loon F; Chakraborty J; Ahmed F; Rao MR; Khan MR; Yunus M; Huda N
Lancet; 1990 Feb; 335(8684):270-3. PubMed ID: 1967730
[TBL] [Abstract][Full Text] [Related]
19. Vaccine Protection of Bangladeshi infants and young children against cholera: implications for vaccine deployment and person-to-person transmission.
Ali M; Emch M; Yunus M; Sack D; Lopez AL; Holmgren J; Clemens J
Pediatr Infect Dis J; 2008 Jan; 27(1):33-7. PubMed ID: 18162935
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of a bivalent killed whole-cell cholera vaccine over five years: a re-analysis of a cluster-randomized trial.
Fong Y; Halloran ME; Park JK; Marks F; Clemens JD; Chao DL
BMC Infect Dis; 2018 Feb; 18(1):84. PubMed ID: 29463233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
